Stockscreener 앱 받기
9.06
2.37%
-0.22
시간 외 거래:
9.06
전일 마감가:
$9.28
열려 있는:
$9.27
하루 거래량:
750.98K
Relative Volume:
0.73
시가총액:
$959.32M
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-2.932
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
-1.09%
1개월 성능:
+6.59%
6개월 성능:
-27.81%
1년 성능:
-33.82%
1일 변동 폭
$8.96
$9.435
1주일 범위
$8.96
$10.74
52주 변동 폭
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
9.06 | 1.00B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences Q2 Earnings and Catalysts Ahead: A Risky Buy for 12 Months - AInvest
Arcus BiosciencesA Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 - MSN
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) | - GuruFocus
Arcus Biosciences Tops Revenue Forecasts And Drives Pipeline Growth - Finimize
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Reports Strong Q2 2025 Results - TipRanks
Arcus Biosciences earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Arcus Biosciences Q2 revenue beats analyst expectations - MarketScreener
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Stock Titan
Is Arcus Biosciences (NYSE:RCUS) Using Debt In A Risky Way? - 富途牛牛
When is Arcus Biosciences Inc. stock expected to show significant growthIdentify undervalued stocks ready to soar - Jammu Links News
How volatile is Arcus Biosciences Inc. stock compared to the marketTremendous gains - Jammu Links News
What are the technical indicators suggesting about Arcus Biosciences Inc.Free Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Arcus Biosciences Inc. stockHigh-yield investments - Jammu Links News
Should I hold or sell Arcus Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
How does Arcus Biosciences Inc. compare to its industry peersOutstanding capital appreciation - Jammu Links News
What are the latest earnings results for Arcus Biosciences Inc.Outstanding risk-reward balance - Jammu Links News
Why is Arcus Biosciences Inc. stock attracting strong analyst attentionRealize consistent double-digit growth - Jammu Links News
Does Arcus Biosciences Inc. stock perform well during market downturnsTremendous gains - Jammu Links News
What catalysts could drive Arcus Biosciences Inc. stock higher in 2025Free Stock Movement Tracking - Jammu Links News
Arcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA - MSN
How does Arcus Biosciences Inc. generate profit in a changing economyPost Market Planner That Work - Jammu Links News
Arcus Biosciences Advances Phase 1 Study of AB521 in Cancer Treatment - TipRanks
Will Arcus Biosciences Inc. bounce back from current supportEarly Breakout Entry Point Notifications Sent - metal.it
Why Arcus Biosciences Inc. stock attracts strong analyst attentionConsistent Income Focused Trade List Analyzed - beatles.ru
How many analysts rate Arcus Biosciences Inc. as a “Buy”Advanced Screener Report With Low Risk - Jammu Links News
Arcus Biosciences Advances Phase 1 Study for Cancer Treatment - TipRanks
Arcus Biosciences Inc.’s Price Action Aligns with Quant SignalsHigh Yield Stock Screening Results Explained - metal.it
Arcus Biosciences’ SWOT analysis: HIF-2alpha program drives stock outlook By Investing.com - Investing.com South Africa
Arcus Biosciences Inc. Shows Risk Reward Favoring UpsideReal Trader Watchlist of Hot Stocks Released - metal.it
Is it the right time to buy Arcus Biosciences Inc. stockSuperior returns - Jammu Links News
What is Arcus Biosciences Inc. company’s growth strategyMaximize your portfolio’s growth potential - Jammu Links News
New Product Launches: Will They Boost Arcus Biosciences Inc. Stock in 2025Professional Stock Screener - metal.it
What is the dividend policy of Arcus Biosciences Inc. stockGet daily updates on the hottest stocks - Jammu Links News
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):